Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study.
Cristina MussiniAlessandro Cozzi-LepriMarianna MeschiariErika FranceschiniGiulia BurasteroMatteo FaltoniGiacomo FranceschiVittorio IadiserniaSara VolpiAndrea DessilaniLicia GozziJacopo ContiMartina Del MonteJovana MilicVanni BorghiRoberto TonelliLucio BrugioniElisa RomagnoliAntonello PietrangeloElena CorradiniMassimo GirardisStefano BusaniAndrea CossarizzaEnrico Maria CliniGiovanni GuaraldiPublished in: Viruses (2023)
Our data confirm that glucocorticoids + tocilizumab vs. glucocorticoids alone confers a survival benefit only in patients with a CRP > 7.5 mg/dL prior to treatment initiation and the largest effect for a CRP > 15 mg/dL. Large randomized studies are needed to establish an exact cut-off for clinical use.
Keyphrases
- rheumatoid arthritis
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- double blind
- open label
- electronic health record
- clinical trial
- placebo controlled
- density functional theory
- big data
- phase iii
- phase ii
- randomized controlled trial
- disease activity
- machine learning
- molecular dynamics
- deep learning
- artificial intelligence
- data analysis
- smoking cessation